During the past decade, Pharmasite Research, Inc. conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 36 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 19 clinical trials were completed. i.e. 146.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Pharmasite Research, Inc." #1 sponsor was "Eli Lilly and Company" with 11 trials, followed by "Naurex, Inc, an affiliate of Allergan plc" with 7 trials sponsored, "Otsuka Pharmaceutical Development & Commercialization, Inc." with 5 trials sponsored, "Pfizer" with 4 trials sponsored and "Allergan" with 4 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Pharmasite Research, Inc." #1 collaborator was "Alzheimer's Association" with 1 trials as a collaborator, "Clinilabs, Inc." with 1 trials as a collaborator, "National Institute on Aging (NIA)" with 1 trials as a collaborator, "Otsuka America Pharmaceutical" with 1 trials as a collaborator and "Otsuka Pharmaceutical Co., Ltd." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Pharmasite Research, Inc." are "Major Depressive Disorder" (18 trials), "Depressive Disorder, Major" (6 trials), "Alzheimer's Disease" (5 trials), "Episodic Migraine" (3 trials) and "Hot Flashes" (3 trials). Many other conditions were trialed in "Pharmasite Research, Inc." in a lesser frequency.

Most popular intervention types in "Pharmasite Research, Inc." are "Drug" (56 trials), "Device" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (31 trials), "Galcanezumab" (5 trials), "Rapastinel" (5 trials), "ADT" (4 trials) and "placebo" (4 trials). Other intervention names were less common.

The vast majority of trials in "Pharmasite Research, Inc." are 54 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Pharmasite Research, Inc.". undefined are not yet recruiting, 8 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 40 completed trials in Pharmasite Research, Inc., undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Pharmasite Research, Inc., 0 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 41 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 1 trials that are defined as “Not Applicable".